Form 4: Vaxcyte Director Heath Lukatch Receives Significant Equity Compensation

Vaxcyte, Inc. Director Heath Lukatch was granted 3,041 restricted stock units and options to purchase 15,372 shares of common stock as part of his compensation.

Summary

• Director Heath Lukatch of Vaxcyte, Inc. (PCVX) acquired 3,041 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 12, 2025.
• Each RSU represents the contingent right to receive one share of Vaxcyte's Common Stock, with a reported acquisition price of $0.
• These RSUs will fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on Mr. Lukatch's continuous service.
• Mr. Lukatch also acquired stock options to purchase 15,372 shares of Common Stock on June 12, 2025, with an exercise price of $34.46 per share.
• The shares subject to these options will vest monthly and fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on Mr. Lukatch's continuous service.
• Following these transactions, Mr. Lukatch directly beneficially owns 17,216 shares of Common Stock and 15,372 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, which is a positive for aligning management interests with shareholders, but it does not contain new operational or financial performance data to significantly alter sentiment.

Positives

• The grant of equity compensation to Director Heath Lukatch aligns his interests with those of Vaxcyte shareholders, incentivizing long-term performance.
• The acquisition of additional equity by a director can signal confidence in the company's future prospects.

Risks

• The vesting of both the Restricted Stock Units (RSUs) and stock options is subject to the Reporting Person's continuous service through the vesting date, meaning the compensation is contingent on continued employment or board service.

Future Outlook

The vesting schedules for the granted RSUs and stock options, extending to June 12, 2026, or the day prior to the next annual meeting of stockholders, indicate an expectation of continued service from Director Heath Lukatch.

Management Comments

• The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
• The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Industry Context

This Form 4 filing is a standard disclosure for insider transactions, specifically detailing equity compensation granted to a director. Such grants are common practice in the biotechnology and pharmaceutical industries, like Vaxcyte, Inc., to attract and retain executive talent and align their interests with long-term company performance.

Comparison to Industry Standards

• Equity compensation, including Restricted Stock Units (RSUs) and stock options, is a standard component of director and executive compensation packages across the biotechnology and broader corporate sectors.
• The vesting schedules tied to continuous service are typical mechanisms to ensure retention and incentivize long-term commitment, comparable to practices at companies like Moderna, BioNTech, or Pfizer, which also utilize equity grants for their leadership.
• The specific value and number of shares granted would typically be benchmarked against peer companies of similar market capitalization and stage of development within the biotech industry, though this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The grant of equity compensation (Restricted Stock Units and Stock Options) to Director Heath Lukatch by Vaxcyte, Inc. constitutes a related party transaction, as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for broader employee equity programs.
• Director (Heath Lukatch): Receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• Continued service of Director Heath Lukatch to ensure vesting of RSUs and stock options.
• Vesting of 3,041 Restricted Stock Units on or before June 12, 2026.
• Monthly vesting of 15,372 stock options, fully vesting on or before June 12, 2026.

Key Dates

Keywords

Vaxcyte, PCVX, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance, Biotechnology